- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
MassBio’s First-Ever Partnering Week to Connect Early-Stage Innovators with Major Life Sciences Organizations
Week-long event aims to help commercialize innovations to reach patients in need.
Taking place from Monday, January 25 to Friday, January 29, 2021, MassBio’s Partnering Week is a week-long event that connects early-stage companies developing breakthrough technologies with leading biopharmaceutical, medical device, diagnostic, and digital health organizations in complementary focus areas for partnering opportunities. Each day is dedicated to one sponsor who will begin with an overview presentation on the organization’s research and development strategy, partnering approaches, therapeutic areas, and 2021 outlook. The sponsor will then host one-on-one meetings with selected startups. The overview sessions are open to the public.
The sponsors of the event and dates of their respective overview sessions are: Biogen (January 25th), Johnson & Johnson Innovation (January 26th), EMD Serono (January 27th), and BeiGene (January 28th).
For more information, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
